Aeglea BioTherapeutics, Inc. (AGLE) Social Stream
AEGLEA BIOTHERAPEUTICS INC (AGLE) Price Targets From Analysts
Use the tables below to see what analysts covering AEGLEA BIOTHERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
---|---|---|---|---|---|---|
2021-12-06 | 4 | $15 | $11 | $13.25 | $12.01 | 10.32% |
2022-02-04 | 4 | $15 | $9 | $12.5 | $12.01 | 4.08% |
2022-04-13 | 4 | $20 | $9 | $12 | $12.01 | -0.08% |
2022-05-05 | 4 | $17 | $9 | $11.25 | $12.01 | -6.33% |
2022-05-08 | 4 | $17 | $7 | $10.75 | $12.01 | -10.49% |
2022-05-09 | 4 | $17 | $7 | $10.5 | $12.01 | -12.57% |
2022-05-11 | 4 | $17 | $7 | $10.25 | $12.01 | -14.65% |
2022-05-23 | 4 | $17 | $4 | $9.5 | $12.01 | -20.9% |
2022-06-02 | 5 | $17 | $1 | $7.25 | $12.01 | -39.63% |
2022-06-03 | 5 | $8 | $1 | $3.25 | $12.01 | -72.94% |
2022-08-05 | 4 | $3 | $1 | $1.666 | $12.01 | -86.13% |
2022-10-28 | 3 | $2 | $2 | $2 | $12.01 | -83.35% |
2023-03-03 | 5 | $3 | $1 | $1.75 | $12.01 | -85.43% |
2023-07-25 | 4 | $2 | $0.9 | $1.45 | $12.01 | -87.93% |
2023-08-11 | 2 | $2 | $0.9 | $1.45 | $12.01 | -87.93% |
2023-08-16 | 2 | $22.5 | $12.5 | $17.5 | $12.01 | 45.71% |
2023-11-10 | 2 | $23 | $12.5 | $17.75 | $12.01 | 47.79% |
The Trend in the Analyst Price Target
AGLE's average price target has moved up $3.61 over the prior 33 months.
AGLE reports an average of 438.04% for its upside potential over the past 49 weeks.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
---|---|---|---|---|---|---|
2023-01-06 | 5 | 3.0 | 1.0 | 1.875 | 0.500 | 275% |
2023-03-03 | 5 | 3.0 | 1.0 | 1.875 | 0.394 | 375.89% |
2023-08-16 | 2 | 22.5 | 12.5 | 17.500 | 0.462 | 3687.88% |
2023-08-16 | 2 | 0.9 | 0.5 | 0.700 | 0.462 | 51.52% |
2023-11-10 | 2 | 23.0 | 12.5 | 17.750 | 9.490 | 87.04% |
AGLE Broker Recommendations Summary
Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
---|---|---|---|---|---|---|
2 | 1 | 0 | 1 | 0 | 0 | 2 |
The Trend in the Broker Recommendations
Over the past 46 months, AGLE's average broker recommendation rating worsened by 0.67.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, AEGLEA BIOTHERAPEUTICS INC's average analyst price target is higher than 159.82% of them.
- In the context of all US stocks, AEGLEA BIOTHERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 240.22% of them.
- In the context of Healthcare stocks, AEGLEA BIOTHERAPEUTICS INC's number of analysts covering the stock is higher than 400.25% of them.
- In the context of stocks in the small market cap category, AEGLEA BIOTHERAPEUTICS INC's variance in analysts' estimates is lower than -1691.3% of them.
In the Pharmaceutical Products industry, CTMX, SYBX, and ACRS are the three stocks most similar to AEGLEA BIOTHERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for AGLE? Use POWR Ratings for clearer insight into price direction.